Literature DB >> 25878756

Importance of acrocyanosis in delayed walking.

Uluç Yiş1, İpek Polat1, Pakize Karakaya1, Müge Ayanoğlu1, Ayşe Semra Hiz1.   

Abstract

We present a four-year-old wth ethylmalonic encephalopathy who presented with delayed walking. She had bilateral hyperintense lesions in the basal ganglia. Molecular analysis revealed a homozygous c.3G>T mutation in the ETHE1 gene. She did not have typical findings of the disease including recurrent petechia, chronic diarrhea and acrocyanosis was very subtle and orthostatic. She benefited from riboflavine and Q10 treatments. We suggest that acrocyanosis should be questioned and examined in patients with motor delay.

Entities:  

Keywords:  Acrocyanosis; ethylmalonic encephalopathy; motor delay

Year:  2015        PMID: 25878756      PMCID: PMC4395958          DOI: 10.4103/1817-1745.154368

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


Introduction

Ethylmalonic encephalopathy is a rare neurometabolic disorder caused by mutations in the ETHE1 gene. We present a four-year-old girl who presented with delayed walking. Acrocyanosis was very subtle and orthostatic in her. We suggest that acrocyanosis should be questioned and examined in patients with motor delay.

Case Report

A 4-year-old girl was admitted for the investigation for delayed walking. She started to walk at the age of 2.5 years. Since she started to walk, she had tip toe walking, clumsy feet, and easy fatigability while climbing stairs. She was easily falling when she attempted to perform fast run. The symptoms increased at times when she had an infection. She was born at term with a birth weight of 3150 g. The parents were consanguineous. Neurologic examination revealed esotropia in the left eye, mild spasticity in lower extremities with increased deep tendon reflexes, bilateral clonus, and Babinski sign. Brain magnetic resonance imaging revealed bilateral punctuate hyperintense T2 signals in the basal ganglia with minor lactate peak on spectroscopy. Plasma lactic acid level was minimally elevated (2.92 [0.5–2.2] mmol/L). Plasma acylcarnitine analysis was normal and urine organic acid analyses revealed a slight increase in excretion of ethylmalonic acid (41 [1.7–14.6] mmol/mol creatinine). There was no history of diarrhea, petechiae, ecchimoses and acute metabolic decompensation. Molecular analysis revealed a homozygous c. 3 G >T mutation in the ETHE1 gene, previously reported in association with ethylmalonic encephalopathy, which alters the initiator methionine codon. After the genetic diagnosis, we observed that the patient had mild orthostatic acrocyanosis in feet [Figure 1]. Riboflavine (100 mg/day) and coenzyme Q10 (20 mg/kg/day) were started.
Figure 1

Acrocyanosis of the feet

Acrocyanosis of the feet

Discussion

Ethylmalonic encephalopathy is a rare neurometabolic disorder caused by mutations in the ETHE1 gene. Neurodevelopmental delay and regression, pyramidal and extrapyramidal involvement, episodes of acrocyanosis, recurrent petechiae and chronic diarrhea are cardinal features of the disease.[1] Characteristic metabolic findings include lactic acidemia, elevated plasma C4 and C5 acylcarnitines, C4-5 acyglycines and remarkable ethylmalonic aciduria. Brain magnetic resonance findings are not considered specific for the disorder and include frontotemporal atrophy and areas of high signal in the caudate nuclei, putamina and posterior fossa. Fatal neurologic deterioration due to intercurrent infection frequently occurs in infancy or early childhood, but a few children with a milder, chronic form of this disorder have been reported.[2] Our patient had milder form of the disease with prominent pyramidal tract signs, bilateral punctuate hyperintense T2 signals in the basal ganglia and mildly elevated serum lactic acid and urinary ethylmalonic acid. Not all patients with ethylmalonic encephalopathy have classical findings like recurrent petechia, orthostatic acrocyanosis and chronic diarrhea leading to diagnosis. We observed mild orthostatic acrocyanosis just after the genetic confirmation of the disease. Acrocyanosis is a peripheral vascular disorder characterized by bluish discoloration of the skin and mucous membrane due to diminished oxyhemoglobin. It is caused by chronic vasospasm of small cutaneous arteries and arterioles along with compensatory dilatation in the capillary and postcapillary venules. It can be both primary and secondary to psychiatric, neurologic, autoimmune, infective and metabolic causes. Inherited metabolic disorders causing acrocyanosis include fucosidosis, hyperoxaluria type I and mitochondrial disorders with onset in early infancy and multisystem involvement. Orthostatic acrocyanosis is one of the important signs of ethylmalonic encephalopathy.[3] ETHE1 encodes a mitochondrial sulfur dioxygenase that takes part in aerobic energetic exploitation of and detoxification from sulfide. Sulfide can act as a vasodilator thus explaining the acrocyanosis and can be toxic for the microvessels thus explaining the petechiae.[4] In conclusion, acrocyanosis may be subtle in cases with ethylmalonic encephalopathy, it should be questioned and examined in patients presenting with motor delay and bilateral hyperintense lesions in the basal ganglia.
  4 in total

1.  Ethylmalonic encephalopathy: further clinical and neuroradiological characterization.

Authors:  Salvatore Grosso; Rosa Mostardini; Maria Angela Farnetani; Massimo Molinelli; Rosario Berardi; Carlo Dionisi-Vici; Cristiano Rizzo; Guido Morgese; Paolo Balestri
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 2.  Altered sulfide (H(2)S) metabolism in ethylmalonic encephalopathy.

Authors:  Valeria Tiranti; Massimo Zeviani
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

3.  Ethylmalonic aciduria: an organic acidemia with CNS involvement and vasculopathy.

Authors:  P T Ozand; M Rashed; D S Millington; N Sakati; S Hazzaa; Z Rahbeeni; A al Odaib; N Youssef; A Mazrou; G G Gascon
Journal:  Brain Dev       Date:  1994-11       Impact factor: 1.961

4.  Acrocyanosis: an overview.

Authors:  Sudip Das; Arunasis Maiti
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

  4 in total
  6 in total

1.  Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine.

Authors:  Mustafa Kılıç; Özge Dedeoğlu; Rahşan Göçmen; Selman Kesici; Deniz Yüksel
Journal:  Metab Brain Dis       Date:  2016-11-09       Impact factor: 3.584

2.  Severe early onset ethylmalonic encephalopathy with West syndrome.

Authors:  Laura Papetti; Giacomo Garone; Livia Schettini; Carla Giordano; Francesco Nicita; Paola Papoff; Massimo Zeviani; Vincenzo Leuzzi; Alberto Spalice
Journal:  Metab Brain Dis       Date:  2015-07-21       Impact factor: 3.584

3.  Neurological and Vascular Manifestations of Ethylmalonic Encephalopathy.

Authors:  Ali Reza Tavasoli; Parastoo Rostami; Mahmoud Reza Ashrafi; Parvaneh Karimzadeh
Journal:  Iran J Child Neurol       Date:  2017

4.  ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts.

Authors:  Mateus Grings; Bianca Seminotti; Anuradha Karunanidhi; Lina Ghaloul-Gonzalez; Al-Walid Mohsen; Peter Wipf; Johan Palmfeldt; Jerry Vockley; Guilhian Leipnitz
Journal:  Sci Rep       Date:  2019-09-02       Impact factor: 4.379

Review 5.  Acrocyanosis - A Symptom with Many Facettes.

Authors:  Uwe Wollina; André Koch; Dana Langner; Gesina Hansel; Birgit Heinig; Torello Lotti; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-01-10

Review 6.  Riboflavin Deficiency-Implications for General Human Health and Inborn Errors of Metabolism.

Authors:  Signe Mosegaard; Graziana Dipace; Peter Bross; Jasper Carlsen; Niels Gregersen; Rikke Katrine Jentoft Olsen
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.